TRIM56

Across TCGA pan-cancer cohorts, TRIM56 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of TRIM56’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TRIM56 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TRIM56 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

HNSC, PDAC, and COAD are the cancer types where TRIM56 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRIM56 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+0.214	<.001	8	view →
PDAC	Female	II,III,IV	−0.359	<.001	7	view →
COAD	Female	II,III,IV	+0.082	.004	6	view →
LSCC	Male	All	+0.067	<.001	4	view →
CCRCC	All	All	+0.039	.017	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

TRIM56–HNSC

Open the HNSC breakdown →